Latest News and Press Releases

Proceeds will fund further clinical development of the company’s true theranostic pipeline and expansion of the global production and manufacturing network for copper-based...

61Cu-NuriPro™ detected more lesions up to 4 hours post-administration in 50% of patients, not visualized by 18F-piflufolastat PET1,2 Dosimetry data highlight favorable tumor-to-background ratio with...

New study arm (Part D) is part of the broad clinical development plan of the ITM-91/ITM-94 theranostic program in patients with Carbonic Anhydrase IX (CAIX)-expressing tumors Part D builds on...

Boston, June 17, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, the “Radiopharmaceuticals: Technologies and Global Markets” is expected to grow from $10.3 billion in 2024...

Garching / Munich, Germany, and Grenoble, France, June 16, 2025 – ITM Isotope Technologies Munich SE (ITM) and the Institut Laue-Langevin (ILL), today announced an extension of their collaboration for...

Garching / Munich, Germany, June 13, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will provide further analysis from its...

Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Radiotherapy Devices Market Opportunities and Strategies to 2033" has been added to ResearchAndMarkets.com's offering. The global radiotherapy...

Debt capital to support commercial readiness and potential U.S. launch of n.c.a. 177Lu-edotreotide (ITM-11), following positive Phase 3 resultsFlexible funding structure enables continued advancement...

Boston, May 22, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “High-Throughput Screening: Technologies and Global Markets” is expected to grow from $23.8 billion in 2024...

Garching / Munich, Germany, April 09, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the election of Barbara Weber, M.D., to its...